Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$84.86

1.21 (1.45%)

12:04
12/19/18
12/19
12:04
12/19/18
12:04

AbbVie and Voluntis to develop companion digital therapeutics

Voluntis announces today that it has entered into a collaboration with AbbVie, a research-based global biopharmaceutical company, to enhance patient care coordination in immunology with innovative digital therapeutic software. Together the companies will leverage Voluntis' proven Theraxium technology to make this new solution available to patients and providers in the United States. Pierre Leurent, CEO of Voluntis: "This collaboration illustrates the value of Theraxium in powering next-generation digital therapeutics in wide-ranging therapeutic areas."

ABBV AbbVie
$84.86

1.21 (1.45%)

12/13/18
12/13/18
UPGRADE

Outperform
Galapagos NV upgraded to Outperform at Credit Suisse after removal of headwinds
As previously reported, Credit Suisse analyst Vamil Divan upgraded Galapagos NV (GLPG) to Outperform from Neutral following removal of headwinds and given the multiple assets that the company now has in mid-late stage development. Among the headwinds were the cystic fibrosis franchise, which he had concern about and is being run by AbbVie (ABBV), and clarity on the U.S. filing timelines for lead asset filgotinib, the analyst notes. Divan also raised his price target on Galapagos NV shares to EUR130 from EUR90.
11/23/18
RHCO
11/23/18
NO CHANGE
Target $135
RHCO
Buy
AbbVie gets 'another leg of growth' on FDA approval of Venclexta, says SunTrust
SunTrust analyst John Boris kept his Buy rating and $135 price target on AbbVie (ABBV), saying the latest FDA approval for its Venclexta for the treatment of newly-diagnosed acute myeloid leukemia in adults aged 75 years or more that is jointly marketed with Roche (RHHBY) gives the company "another leg of growth" with over $1B in estimated peak sales. The analyst sees the results from a phase-3 Bellini study evaluating the combination of Venclexta, Velcade, and dexamethasone in relapsed and refractory Multiple Myeloma expected in the first half of 2019 as the next potential catalyst for the program.
11/06/18
ARGS
11/06/18
NO CHANGE
Target $115
ARGS
Buy
AbbVie price target lowered to $115 from $130 at Argus
Argus analyst David Toung lowered his price target on AbbVie to $115 to reflect the competitive environment for its Humira sales from biosimilars in Europe, but also kept his Buy rating and raised his FY18 EPS view by 9c to $7.91 and FY19 by 12c to $9.00. The analyst says Humira should continue to post "solid growth" in the U.S. markets, and also cites the prospects of its Imbruvica, Venclexta Orilissa and hepatitis C drugs along with its remaining product pipeline. Toung contends that the "incremental sales of new faster-growing products can more than offset the expected decline in overseas sales of Humira".
11/02/18
PIPR
11/02/18
NO CHANGE
PIPR
AbbVie Q3 results do not convince Piper Jaffray to get off sidelines
Piper Jaffray analyst Christopher Raymond maintained a Neutral rating on AbbVie after the company's Q3 earnings results, which Raymond noted were better than expected. However, the analyst was cautious given management's indication of growing headwinds, which he believes "portend a meaningful downward revision to FY19 consensus." Additionally, Raymond sees AbbVie "married to the prospects of Humira," which he believes now faces international headwinds competing with four biosimilars.

TODAY'S FREE FLY STORIES

BABA

Alibaba

$173.57

4.39 (2.59%)

07:22
10/22/19
10/22
07:22
10/22/19
07:22
Recommendations
Alibaba analyst commentary  »

Daiwa expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 19

    Nov

ORTX

Orchard Therapeutics

$12.09

0.1 (0.83%)

07:21
10/22/19
10/22
07:21
10/22/19
07:21
Hot Stocks
Orchard Therapeutics presents data from OTL-200 in patients with MLD »

Orchard Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SWI

SolarWinds

$19.05

0.22 (1.17%)

07:20
10/22/19
10/22
07:20
10/22/19
07:20
Downgrade
SolarWinds rating change  »

SolarWinds downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

CHTR

Charter

$438.01

-2.45 (-0.56%)

07:20
10/22/19
10/22
07:20
10/22/19
07:20
Recommendations
Charter analyst commentary  »

Charter price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

NVCN

Neovasc

$3.72

0.17 (4.79%)

07:18
10/22/19
10/22
07:18
10/22/19
07:18
Hot Stocks
Neovasc announces multiple presentations featuring Neovasc Reducer »

Neovasc announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KDMN

Kadmon

$3.08

0.17 (5.84%)

07:17
10/22/19
10/22
07:17
10/22/19
07:17
Hot Stocks
Kadmon reports FDA approval of Clovique generic product »

Kadmon Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTU

Intuit

$262.05

-0.49 (-0.19%)

07:17
10/22/19
10/22
07:17
10/22/19
07:17
Downgrade
Intuit rating change  »

Intuit downgraded to In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

QTRH

Quarterhill

$1.29

0.05 (4.03%)

07:16
10/22/19
10/22
07:16
10/22/19
07:16
Hot Stocks
Quarterhill names David Cortens as interim CFO, succeeding Shaun McEwan »

Quarterhill announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCY

Oncolytics

$0.47

-0.0138 (-2.83%)

, PFE

Pfizer

$36.45

-0.01 (-0.03%)

07:16
10/22/19
10/22
07:16
10/22/19
07:16
Hot Stocks
Oncolytics, PrECOG announce collaboration for Bracelet-1 study in metastatic BC »

Oncolytics Biotech (ONCY)…

ONCY

Oncolytics

$0.47

-0.0138 (-2.83%)

PFE

Pfizer

$36.45

-0.01 (-0.03%)

MKGAY

Merck KGaA

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 06

    Nov

  • 07

    Dec

KMT

Kennametal

$29.76

-0.97 (-3.16%)

07:16
10/22/19
10/22
07:16
10/22/19
07:16
Recommendations
Kennametal analyst commentary  »

Kennametal price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 05

    Nov

  • 14

    Nov

ETON

Eton Pharmaceuticals

$5.66

-0.395 (-6.52%)

07:14
10/22/19
10/22
07:14
10/22/19
07:14
Hot Stocks
Eton Pharmaceuticals announces FDA approval of Biorphen injection »

Eton Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Mar

WDAY

Workday

$154.10

-0.54 (-0.35%)

07:14
10/22/19
10/22
07:14
10/22/19
07:14
Upgrade
Workday rating change  »

Workday upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPS

UPS

$118.56

1.23 (1.05%)

07:13
10/22/19
10/22
07:13
10/22/19
07:13
Hot Stocks
UPS announces retirement of COO Jim Barber »

UPS announced COO Jim…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

IPG

Interpublic Group

$20.79

0.14 (0.68%)

07:11
10/22/19
10/22
07:11
10/22/19
07:11
Earnings
Interpublic Group 'on track' to deliver high end of 2%-3% organic growth in 2019 »

Consensus $8.65B. CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

AAPL

Apple

$240.49

4.2 (1.78%)

07:11
10/22/19
10/22
07:11
10/22/19
07:11
Recommendations
Apple analyst commentary  »

KeyBanc views near-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

PG

Procter & Gamble

$119.04

1.55 (1.32%)

07:10
10/22/19
10/22
07:10
10/22/19
07:10
Hot Stocks
Procter & Gamble: Q1 operating profit margin increased 280 basis points »

Operating profit margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

PG

Procter & Gamble

$119.04

1.55 (1.32%)

07:09
10/22/19
10/22
07:09
10/22/19
07:09
Hot Stocks
Procter & Gamble: Q1 reported gross margin increased 180 basis points »

Q1 Reported gross margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

VCYT

Veracyte

$26.18

1.52 (6.16%)

07:09
10/22/19
10/22
07:09
10/22/19
07:09
Hot Stocks
Veracyte announces preliminary nasal swab test clinical data »

Veracyte announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 12

    Dec

PRVB

Provention Bio

$6.09

-0.48 (-7.31%)

07:09
10/22/19
10/22
07:09
10/22/19
07:09
Hot Stocks
Provention Bio announces results from Phase 2a PRINCE clinical trial »

Provention Bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLAN

Anaplan

$44.35

0.34 (0.77%)

07:09
10/22/19
10/22
07:09
10/22/19
07:09
Upgrade
Anaplan rating change  »

Anaplan upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPG

Interpublic Group

$20.79

0.14 (0.68%)

07:08
10/22/19
10/22
07:08
10/22/19
07:08
Earnings
Interpublic Group reports Q3 adjusted EPS 49c, consensus 47c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

CSIQ

Canadian Solar

$18.51

0.39 (2.15%)

07:07
10/22/19
10/22
07:07
10/22/19
07:07
Hot Stocks
Canadian Solar awarded 30 MWp project in Japan »

Canadian Solar announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

BBY

Best Buy

$71.51

0.89 (1.26%)

07:06
10/22/19
10/22
07:06
10/22/19
07:06
Hot Stocks
Best Buy announces free next-day shipping for holiday season »

Best Buy announced free…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

SGEN

Seattle Genetics

$100.86

13.44 (15.37%)

07:06
10/22/19
10/22
07:06
10/22/19
07:06
Recommendations
Seattle Genetics analyst commentary  »

Seattle Genetics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 07

    Dec

AER

AerCap

$56.60

0.65 (1.16%)

, BA

Boeing

$331.12

-12.97 (-3.77%)

07:06
10/22/19
10/22
07:06
10/22/19
07:06
Hot Stocks
AerCap delivers new Boeing 787-9 Dreamliner to Air New Zealand »

AerCap Holdings (AER) has…

AER

AerCap

$56.60

0.65 (1.16%)

BA

Boeing

$331.12

-12.97 (-3.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 08

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.